QUANTIFICATION OF METASTATIC PROSTATE CANCER WHOLE-BODY TUMOR BURDEN WITH FDG PET PARAMETERS AND ASSOCIATIONS WITH OVERALL SURVIVAL AFTER FIRST LINE ABIRATERONE OR ENZALUTAMIDE: A SINGLE-CENTER RETROSPECTIVE COHORT STUDY.

MLA

Wibmer, Andreas G., et al. “Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with Fdg Pet Parameters and Associations with Overall Survival After First Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study.” Journal of Nuclear Medicine, vol. 62, no. 3, Mar. 2021, pp. 1–24. EBSCOhost, https://doi.org/10.2967/jnumed.120.256602.

APA

Wibmer, A. G., Morris, M., Gonen, M., Junting Zheng, Hricak, H., Larson, S., Scher, H. I., & Vargas, H. A. (2021). Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with Fdg Pet Parameters and Associations with Overall Survival After First Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study. Journal of Nuclear Medicine, 62(3), 1–24. https://doi.org/10.2967/jnumed.120.256602

Chicago

Wibmer, Andreas G., Michael Morris, Mithat Gonen, Junting Zheng, Hedvig Hricak, Steven Larson, Howard I. Scher, and Hebert Alberto Vargas. 2021. “Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with Fdg Pet Parameters and Associations with Overall Survival After First Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study.” Journal of Nuclear Medicine 62 (3): 1–24. doi:10.2967/jnumed.120.256602.